BackgroundForeign‐born, HIV‐infected persons are at risk for sub‐clinical parasitic infections acquired in their countries of origin. This study presents the results of this screening program.MethodsA prospective, descriptive study was designed to include all the immigrant patients diagnosed of HIV infection attending in Hospital Central de Asturias, Spain, 2006–2011. We included demographic variables, CD4+cells count and viral load at time of diagnosis. Screening comprised blood count, biochemistry, basic urinalysis, hepatitis B virus (HBV), HCV, strongyloidiasis and schistosomiasis serologic analysis, stool parasites, blood test for filarias, PCR for malaria and Chagas disease serologic analysis and PCR in persons from Latin America. Qualitative variables were compared using the χ2 test, the Fisher exact test, when necessary. For quantitative variables, the Student t test for nonpaired variables or the Mann‐Whitney U test were used. Significance was designated at p<0.05.Results57 patients were analyzed. 70% are sub‐Saharan immigrant and the rest Latin American. The most frequent countries of origin were Equatorial Guinea (43%), Nigeria (10%), Senegal (9%), Colombia (9%). Average time in Spain: 1,061 days (3–9,876). Average Cd4+cells were 209 cells/mm3. The average viral load were 47,000 RNA viral copies. Intestinal parasites were diagnosed in 27 patients: T. trichuria (22%), strongyloidiasis (11%), amebiasis (7%), and schistosomiasis (5%), G. intestinalis (4%). All infections by T. trichuria were diagnosed in Equatorial Guinea patients. Other parasites diseases were: filariasis by M. perstans (9%); malaria (9%, all from Equatorial Guinea), Chagas disease (4%). Eight patients had chronic hepatitis B virus and 2 patients had HCV hepatitis. 19% of patients had latent syphilis, significantly more frequent in sub‐Saharan patients (9 vs 2; p=0.04). In 12 patients the screening did not show any disease.ConclusionsGiven the high prevalence of certain parasite infections and the potential lack of suggestive symptoms and signs, selected screening for strongyloidiasis and schistosomiasis or use of empiric antiparasitic therapy may be appropriate among foreign‐born, HIV‐infected patients. Identifying and treating helminth infections could prevent long‐term complications.
Accelerator Research and Innovation for European Science and Society, ARIES, is an initiative funded by the European Union. The activity comprises three major categories: Joint Research Activities; Transnational Access;Network Activities. One of 17 activities is a network related to Advanced Diagnostics at Accelerators, ADA with the task of strengthening collaborations between international laboratories and for coordinated R&D inbeam diagnostics. This is performed by organizing Topical Workshops on actual developments and supporting interchange of experts between different labs. Since the start of the project in May 2017 four Topical Workshops were organized, each with 30-45 participants. Future workshops will address actual topics.
CompactLight (XLS) is an International Collaboration of 24 partners and 5 third parties, funded by the European Union through the Horizon 2020 Research and Innovation Programme. The main goal of the project, which started in January 2018 with a duration of 36 months, is the design of an hard X-ray FEL facility beyond today's state of the art, using the latest concepts for bright electron photo-injectors, high-gradient accelerating structures, and innovative short-period undulators. The specifications of the facility and the parameters of the future FEL are driven by the demands of potential users and the associated science cases. In this paper we will give an overview on the ongoing activities and the major results achieved until now.
Background: The COVID-19 pandemic has disrupted routine hospital services globally. This study estimated the total number of adult elective operations that would be cancelled worldwide during the 12 weeks of peak disruption due to COVID-19. Methods: A global expert response study was conducted to elicit projections for the proportion of elective surgery that would be cancelled or postponed during the 12 weeks of peak disruption. A Bayesian β-regression model was used to estimate 12-week cancellation rates for 190 countries. Elective surgical case-mix data, stratified by specialty and indication (surgery for cancer versus benign disease), were determined. This case mix was applied to country-level surgical volumes. The 12-week cancellation rates were then applied to these figures to calculate the total number of cancelled operations. Results: The best estimate was that 28 404 603 operations would be cancelled or postponed during the peak 12 weeks of disruption due to COVID-19 (2 367 050 operations per week). Most would be operations for benign disease (90·2 per cent, 25 638 922 of 28 404 603). The overall 12-week cancellation rate would be 72·3 per cent. Globally, 81·7 per cent of operations for benign conditions (25 638 922 of 31 378 062), 37·7 per cent of cancer operations (2 324 070 of 6 162 311) and 25·4 per cent of elective caesarean sections (441 611 of 1 735 483) would be cancelled or postponed. If countries increased their normal surgical volume by 20 per cent after the pandemic, it would take a median of 45 weeks to clear the backlog of operations resulting from COVID-19 disruption. Conclusion: A very large number of operations will be cancelled or postponed owing to disruption caused by COVID-19. Governments should mitigate against this major burden on patients by developing recovery plans and implementing strategies to restore surgical activity safely.